Pfizer (PFE)

HC Wainwright backs Achieve Life Sciences with a Buy rating as cytisinicline nears potential 2026 FDA approval, targeting a large smoking cessation market.

Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Thursday and uncover the stocks that are leading the way in terms of trading volume and market attention.

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

You won't find many stocks with a juicier dividend and more attractive valuation than this big pharma stock.

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q2, starting with Viatris (NASDAQ:VTRS).

San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet designed to treat obesity and other metabolic disorders. The sharp downturn, which saw the company's shares plummet by over 30% in early trading,

Pfizer's yield is high, and so too is its payout ratio.

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.

Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table?

Intel continued its winning run amid news of new strategic investment, while Nvidia saw activity as traders geared up for its quarterly results due next week.

Let's have a look at what is happening on the US markets on Monday. Below you can find the most active S&P500 stocks in today's session.

These three businesses have been raising their payouts for at least 16 consecutive years.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with Zoetis (NYSE:ZTS).

These blue chip healthcare stocks could still deliver strong long-term returns.

Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath.

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

Discover three undervalued dividend stocks under $50 that offer income, growth potential, and strong total returns for value investors

Pfizer beat expectations last quarter and it raised its guidance.

Markets watch for the Trump–Putin meeting tomorrow that could impact Russia–Ukraine peace talks. Analysts see 24,600 as a make-or-break level for Nifty ahead of weekly expiry volatility.

Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Wednesday and uncover the stocks that are leading the way in terms of trading volume and market attention.

The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.